MOESM1 of Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition

Additional file 1: Figure S1. Antitumor effect of RT, IC, anti-CTLA-4, and anti-CD40/CpG against 9464D-GD2 neuroblastoma. Tumor growth curves are shown for mice bearing intradermal 9464D-GD2 tumors (about 50mm3) that were untreated or treated with RT alone, or RT and IT-IC and anti-CTLA-4, or RT and anti-CD40/CpG, or IT-IC and anti-CTLA-4 and anti-CD40/CpG, or RT and combined IT-IC, anti-CTLA-4, and anti-CD40/CpG. Tumor-free mice on day 30 (if any) are denoted as number of CR of total mice in the group. Combined treatment with RT, IT-IC, anti-CTLA-4, and anti-CD40/CpG resulted in complete tumor regression in one mouse and in the strongest tumor growth suppression in other mice.